Institution
Gdańsk Medical University
Education•Gdańsk, Poland•
About: Gdańsk Medical University is a education organization based out in Gdańsk, Poland. It is known for research contribution in the topics: Population & Cancer. The organization has 4893 authors who have published 11216 publications receiving 260523 citations.
Topics: Population, Cancer, Medicine, Blood pressure, Transplantation
Papers published on a yearly basis
Papers
More filters
••
TL;DR: These studies implicate conserved roles for Six2 and Bmp4 in the development of the renal system, which could affect kidney development at multiple stages, leading to the congenital anomalies observed in patients with RHD.
Abstract: Renal hypodysplasia (RHD) is characterized by reduced kidney size and/or maldevelopment of the renal tissue following abnormal organogenesis. Mutations in renal developmental genes have been identified in a subset of affected individuals. Here, we report the first mutations in BMP4 and SIX2 identified in patients with RHD. We detected 3 BMP4 mutations in 5 RHD patients, and 3 SIX2 mutations in 5 different RHD patients. Overexpression assays in zebrafish demonstrated that these mutations affect the function of Bmp4 and Six2 in vivo. Overexpression of zebrafish six2.1 and bmp4 resulted in dorsalization and ventralization, respectively, suggesting opposing roles in mesendoderm formation. When mutant constructs containing the identified human mutations were overexpressed instead, these effects were attenuated. Morpholino knockdown of bmp4 and six2.1 affected glomerulogenesis, suggesting specific roles for these genes in the formation of the pronephros. In summary, these studies implicate conserved roles for Six2 and Bmp4 in the development of the renal system. Defects in these proteins could affect kidney development at multiple stages, leading to the congenital anomalies observed in patients with RHD.
191 citations
••
TL;DR: Fostamatinib produced clinically‐meaningful responses in ITP patients including those who failed splenectomy, thrombopoietic agents, and/or rituximab and is a novel ITP treatment option that targets an important mechanism of ITP pathogenesis.
Abstract: Spleen tyrosine kinase (Syk) signaling is central to phagocytosis-based, antibody-mediated platelet destruction in adults with immune thrombocytopenia (ITP). Fostamatinib, an oral Syk inhibitor, produced sustained on-treatment responses in a phase 2 ITP study. In two parallel, phase 3, multicenter, randomized, double-blind, placebo-controlled trials (FIT1 and FIT2), patients with persistent/chronic ITP were randomized 2:1 to fostamatinib (n = 101) or placebo (n = 49) at 100 mg BID for 24 weeks with a dose increase in nonresponders to 150 mg BID after 4 weeks. The primary endpoint was stable response (platelets ≥50 000/μL at ≥4 of 6 biweekly visits, weeks 14-24, without rescue therapy). Baseline median platelet count was 16 000/μL; median duration of ITP was 8.5 years. Stable responses occurred in 18% of patients on fostamatinib vs. 2% on placebo (P = .0003). Overall responses (defined retrospectively as ≥1 platelet count ≥50 000/μL within the first 12 weeks on treatment) occurred in 43% of patients on fostamatinib vs. 14% on placebo (P = .0006). Median time to response was 15 days (on 100 mg bid), and 83% responded within 8 weeks. The most common adverse events were diarrhea (31% on fostamatinib vs. 15% on placebo), hypertension (28% vs. 13%), nausea (19% vs. 8%), dizziness (11% vs. 8%), and ALT increase (11% vs. 0%). Most events were mild or moderate and resolved spontaneously or with medical management (antihypertensive, anti-motility agents). Fostamatinib produced clinically-meaningful responses in ITP patients including those who failed splenectomy, thrombopoietic agents, and/or rituximab. Fostamatinib is a novel ITP treatment option that targets an important mechanism of ITP pathogenesis.
190 citations
••
TL;DR: The parameters proposed quantitatively characterize the RP-HPLC stationary phases and provide a rational explanation for the differences in retention patterns of individual columns observed when applying the conventional empirical testing methods are proposed.
189 citations
••
TL;DR: Advice is provided to prepare for the impact of COVID-19 pandemic on breast cancer patients and advise on how to triage, prioritize and organize diagnostic procedures, surgical, radiation and medical treatments.
187 citations
••
Charité1, Harvard University2, Hebron University3, Geelong Football Club4, University of Leeds5, The Royal Marsden NHS Foundation Trust6, Emory University7, Université libre de Bruxelles8, Hoffmann-La Roche9, Peking Union Medical College10, Huazhong University of Science and Technology11, Gdańsk Medical University12, Institute for Social Security and Services for State Workers13, Siriraj Hospital14, European Institute of Oncology15, University of Sydney16
TL;DR: Adjuvant trastuzumab therapy reduces the risk of relapse similarly across subgroups defined by nodal status and steroid hormone receptor status, even those at relatively low risk for relapse.
187 citations
Authors
Showing all 4927 results
Name | H-index | Papers | Citations |
---|---|---|---|
Magdi H. Yacoub | 109 | 1267 | 52431 |
Virend K. Somers | 106 | 615 | 54203 |
Felix Mitelman | 95 | 578 | 35416 |
Andrzej Slominski | 91 | 469 | 27900 |
Nils Mandahl | 86 | 427 | 25006 |
Fredrik Mertens | 84 | 406 | 28705 |
Enriqueta Felip | 83 | 622 | 53364 |
Pieter E. Postmus | 81 | 384 | 24039 |
Wilhelm Kriz | 73 | 222 | 19335 |
Godefridus J. Peters | 73 | 523 | 28315 |
Jacek Jassem | 73 | 602 | 35976 |
Piotr Rutkowski | 72 | 563 | 42218 |
Thomas Frodl | 70 | 258 | 16469 |
Eric J. Velazquez | 70 | 396 | 27539 |
Argye E. Hillis | 68 | 398 | 22230 |